Robert B. Clarke

Queen Mary University of London — United Kingdom

Medicine · Health Sciences

65h-index21.0kcitations394works8.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(150), Estrogen and related hormone effects(50), Cancer Genomics and Diagnostics(45), Cancer-related Molecular Pathways(38), Breast Cancer Treatment Studies(34)

Publications393 total

Expanded mosaic chromosomal alterations, frailty, and risks of all-cause and cause-specific mortality among Chinese and the UK adults: evidence from two prospective cohorts
BMC Medicine·2025Open Access
Anti-progestin therapy targets hallmarks of breast cancer risk
Nature·2025· 1 citedOpen Access
Label-free DIA-NN enabled RIME (DIANNeR) reveals glucocorticoid receptor interaction networks in breast, bladder, and blood across normal untransformed cells, cancer cell lines, and PDXs
2025· 1 citedOpen Access
HES1 oscillations are required for cell cycle re-entry in oestrogen receptor positive breast cancer cells
2025· 2 citedOpen Access
BLID is a drug-responsive target of FOXO3a and multi-omics analysis reveals survival mechanisms and therapeutic vulnerabilities in BLID-deficient breast cancer cells
Oncology Letters·2025Open Access
Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancer
Cell Communication and Signaling·2025· 4 citedOpen Access
PR+ progenitors contribute to all mammary epithelial lineages
2025Open Access
MYBL2 maintains stemness and promotes theta-mediated end joining in triple negative breast cancer
2025Open Access
A Guide to Breast Cancer Research: An Introduction
Advances in experimental medicine and biology·2025· 1 cited
Buenos Aires Breast Cancer Symposium 2024: bridging basic and clinical research in breast cancer.
PubMed·2025
Can we utilise the circadian clock to target cancer stem cells?
Cancer Letters·2024· 5 citedOpen Access
SUMOylation regulates the aggressiveness of breast cancer-associated fibroblasts
Cellular Oncology·2024· 7 citedOpen Access
State of the Art Modelling of the Breast Cancer Metastatic Microenvironment: Where Are We?
Journal of Mammary Gland Biology and Neoplasia·2024· 8 citedOpen Access
Abstract 4378: Identification of novel TXNIP-dependent antitumor pathways in breast cancer
Cancer Research·2024
Abstract 3281: Silencing of necroptosis related genes in endocrine-resistant breast cancer cells causes PFKFB3 induced arrest of necroptosis and contributes to resistance
Cancer Research·2024
Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer
Proceedings of the National Academy of Sciences·2024· 41 citedOpen Access
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
The Lancet Oncology·2024· 69 citedOpen Access
Proteomics Identifies Osteomodulin as a Promoter of Breast Cancer Bone Metastasis via CDK1 Activation
2023· 3 citedOpen Access
Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research
Journal of Mammary Gland Biology and Neoplasia·2023· 6 citedOpen Access
Subtype-specific circadian clock dysregulation modulates breast cancer biology, invasiveness, and prognosis
2023· 2 citedOpen Access
page 1 of 20Next →

Frequent Co-authors

Anthony Howell(18), Sacha J. Howell(10), Gillian Farnie(8), Bruno M. Simões(8), Katherine Spence(7), Andrew H. Sims(7), Christopher S. Potten(6), Keith Brennan(6), Carlos Caldas(5), Nigel Bundred(5), Élizabeth Anderson(5), Elizabeth Anderson(5), Göran Landberg(5), Denis Alférez(4), Joaquı́n Arribas(3), Elisabetta Marangoni(3), Violeta Serra(3), Hannah Harrison(3), D. Gareth Evans(3), Matthew P. Ablett(3)